RAMI ZIGDON, MBA — CHIEF EXECUTIVE OFFICER, CO-FOUNDER
Mr. Zigdon brings with him strong experience leading technology companies. Prior to founding Todos Medical with Dr. Udi Zelig and Mr. Shmuel Melman, he served as the country manager for Hitachi Semiconductors and Renesas Technology. He also served as a manager at Scitex Corporation (presently a division of Kodak), and as the Chief Technology Officer of NI Medical. Mr. Zigdon has been recognized for his leadership in the development and implementation of effective product development strategies and FDA submissions.
Mr. Zigdon has served as CEO since our inception in 2010 and was appointed as a director of our Company in May 2016. From May 2011 through June 2015, he also served as a director. From 2003 to 2009, Mr. Zigdon served as sales manager for Israel of Renesas Technology, a leading Japanese semiconductors corporation. Prior to this position, Mr. Zigdon served as the manager of Hitachi Semiconductors Israel and as embedded systems group manager at RDT. Mr. Zigdon has held various technical and management positions at Scitex (in Belgium), NI Medical and Spectronix.
Mr. Zigdon holds a BS in Biology from the Hebrew University in Jerusalem where he graduated with honors, a BS in Electrical Engineering from Ben Gurion University of the Negev, Beersheba, and a MBA from the Heriot-Watt University, Edinburgh.
DR. UDI ZELIG, PHD — CHIEF TECHNOLOGY OFFICER
Dr. Udi Zelig is the scientific founder of Todos Medical. He has spent over a decade as a researcher at Ben Gurion University investigating the use of infrared spectroscopic methods for medical diagnosis. Dr. Zelig’s research has been recognized and supported by the Israel Cancer Association and the Ministry of Health’s Office of the Chief Scientist and published in leading medical and biophysics journals and conferences.
Prior to joining Todos full-time, Dr. Zelig served as Chief Technology Officer at Crow Technologies. In January 2012, Dr. Zelig came onboard to serve as the company’s fulltime Chief Technology Officer. Dr. Zelig is a biomedical engineer with research experience of more than a decade in the conducting and managing of in-vitro and clinical experiments. His main research field is applications of infrared spectroscopy for blood cancer detection and investigation of chemotherapeutic drugs influence on blood cells.
Dr. Zelig holds a BS in Nuclear Engineering, and a MS and PhD in biomedical engineering, all from Ben-Gurion University of the Negev, Beersheba.
Dr. JOSEPH WEE — MANAGING DIRECTOR, SINGAPORE
Dr. Joseph Wee was appointed managing director of our Singapore operations in July 2016. Dr. Wee has over 45 years of experience as productivity and business management consultant to SMEs, MNCs, Government Linked Companies and Government Agencies. Dr. Wee has held senior management and directorship positions in over 20 companies, including 3 publicly listed companies. Dr. Wee has also served as a member of Advisory Committees appointed by Government Agencies.
DAVID BEN NAIM, CPA, MBA – CHIEF FINANCIAL OFFICER
Mr. Ben Naim has a distinguished record as Chief Financial officer for companies listed in both the United States and Israel. Since 2014, David has owned and managed DBN Finance which provides full outsourcing financial services to companies located in Israel. Prior to that Mr. Ben Naim was the CFO at Insuline Medical Inc (TASE – INSL) where he reported directly to the CEO and worked closely with the board of directors and its various committees. David has also served in the role of CFO for Crow Technologies (OTCQB – CRWTF) and Ilex Medical Limited (TASE). Other positions held By Mr. Ben Naim include CFO of Microbot Medical (NASDAQ – MBOT) and Vonetize PLC (TASE – VNTZ). Additionally, Mr. Ben Naim held the title of Corporate Controller at Tadiran Telecom Limited. David has earned an MBA from Ono academic college as well as a C.P.A. license from Ramat Gan College.
DR. MEIR SILVER, PHD — VICE PRESIDENT, CLINICAL RESEARCH AND REGULATORY AFFAIRS
Dr. Silver has a proven track record in global life sciences businesses, and developing innovative products and services. He has over twenty years’ experience in the medical device, and pharmaceutical industries, including clinical and pre-clinical imaging for therapeutic indications. He has held executive positions managing R&D, clinical research and operations, sales, marketing, service, and regulatory submissions. Dr. Silver’s experience in leadership positions in medical device and pharmaceuticals, puts him in the unique position to understand market and business operations from functional and technical perspectives. In addition, his experience working in large corporations and small and medium sized companies at different developmental stages lends an exceptional understanding of different business facets and situations. Dr. Silver has over forty peer-reviewed publications and presentations.
Specialties: Molecular and Clinical Imaging, Regulatory Strategy, clinical activities, business development, biomarkers, pharmaceuticals, biotechnology, medical device, medical imaging
DANIEL HIRSCH, MPH – INVESTOR RELATIONS
Mr. Hirsch as over 25 years of experience with a demonstrated history of working with public companies. Mr. Hirsch has management and business development expertise to go along with a strong background in investor relations.